Development of an ObLiGaRe Doxycycline Inducible Cas9 System for Pre-clinical Cancer Drug Discovery


Authors: A. Lundin, M.J. Porritt, H. Jaiswal, F. Seeliger, C. Johansson, M. Maresca et. al.

Journal: Nature Communications

DOI: 10.1038/s41467-020-18548-9

Publication - Abstract

September 29, 2020

mRNA Oncology Nucleic Acid Lipid Nanoparticles

 Abstract

The CRISPR-Cas9 system has increased the speed and precision of genetic editing in cells and animals. However, model generation for drug development is still expensive and time-consuming, demanding more target flexibility and faster turnaround times with high reproducibility. The generation of a tightly controlled ObLiGaRe doxycycline inducible SpCas9 (ODInCas9) transgene and its use in targeted ObLiGaRe results in functional integration into both human and mouse cells culminating in the generation of the ODInCas9 mouse. Genomic editing can be performed in cells of various tissue origins without any detectable gene editing in the absence of doxycycline. Somatic in vivo editing can model non-small cell lung cancer (NSCLC) adenocarcinomas, enabling treatment studies to validate the efficacy of candidate drugs. The ODInCas9 mouse allows robust and tunable genome editing granting flexibility, speed and uniformity at less cost, leading to high throughput and practical preclinical in vivo therapeutic testing.


limit search to this category
Advanced Search

Advanced Search

close
  • Publications
  • Application Notes
  • Posters
  • Workshops
  • Videos & Webinars
  • Articles
Search

Browse by Category

  • Application
    • Diagnostic and Imaging
    • Genetic Medicine
    • Hematology
    • Metabolic Disorders
    • Neuroscience
    • Oncology
    • Skeletal Disorders
    • Targeted Drug Delivery
    • Vaccines
    • Other Applications
    • Cell therapy
  • Formulation
    • Liposomes
    • Nucleic Acid Lipid Nanoparticles
    • Polymeric Nanoparticles
    • Other Formulations
  • Payload
    • DNA
    • microRNA
    • mRNA
    • siRNA
    • Small Molecule Drugs
    • Other Payloads


related content

Publication - Summary

Jun 03, 2015
Biomaterials

A Highly Tumor-Targeted Nanoparticle of Podophyllotoxin Penetrated Tumor Core and Regressed Multidrug Resistant Tumors

A. Roy, M.J. Ernsting, E. Undzys, S.D. Li

Small Molecule Drugs Polymeric Nanoparticles Oncology

Many chemotherapeutic anticancer agents target vital components of cell division and inhibit survival and growth of cancer cells. Anti-tubulin agents for example, target the microtubule complex formed during mitosis and result in cell apoptosis. Read More



Publication - Summary

Dec 19, 2017
Cell Reports

Systemic Messenger RNA Therapy as a Treatment for Methylmalonic Acidemia

D. An, J.L. Schneller, A. Frassetto, S. Liang, X. Zhu, J.S. Park, M. Theisen, S.J. Hong, J. Zhou J, R. Rajendran, B. Levy, R. Howell, G. Besin, V. Presnyak, S. Sabnis, K.E. Murphy-Benenato, E.S. Kumarasinghe, T. Salerno and P.G.V. Martini PGV

mRNA Metabolic Disorders Nucleic Acid Lipid Nanoparticles

Inborn errors of metabolism (IEMs) can be relatively straight forward to screen for and diagnose; these disorders however, have currently very limited options for treatment. Methylmalonic acidemia (MMA), is an IEM caused by complete or partial defi...

Read More


Sign Up and Stay Informed
Sign up today to automatically receive new Cytiva, formerly Precision NanoSystems application notes, conference posters, relevant science publications, and webinar invites.
Sign Up